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INTRODUCTION
Endometrial cancer is the most common malignancy of 
the fe  male reproductive tract in developed countries [1]. It 
affects mainly postmenopausal women and only 20% of wo­
men will be diagnosed before menopause. The prognosis is 
usually good because approximately 72% of cases are diag­
no  sed at stage I [2]. It has commonly been classified into 
two major clinicopathologic types, type I and type II [3]. It is 
currently known that these two types of endometrial car  ci­
nomas show different molecular alterations. The most fre­
quent early molecular defects of endometrioid carcinomas 
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Objective: To determine matrix metalloproteinase­2 and survivin expressions in endometrial cancers, their relation to clinical 
and histologic parameters and to investigate any difference in the expression of these markers between endometrioid and non­
endometrioid cancers.
Methods: Ninety­five patients with endometrial cancer, were included. Matrix metalloproteinase­2 and survivin expressions 
were analyzed immunohistochemically from paraffin­embedded tissues by using specific monoclonal antibodies.
Results: Survivin nuclear expression was higher in endometrioid cancer as compared to non  endometrioid cancer (p=0.040), 
but there was no difference for cytoplasmic survivin and matrix metalloproteinase­2 expressions between type I and type 
II carcinomas. Survivin cytoplasmic staining was significantly lower in patients with deep myometrial invasion (p=0.038). 
Nuclear expression of survivin is decreased in histologic grade 3 tumors compared to grade 1 and 2 tumors (p=0.013), but 
there is no difference between grade 1 and 2. We did not find any statistically significant difference between survivin or matrix 
metalloproteinase­2 expressions and survival.
Conclusion: Survivin and matrix metalloproteinase­2 are present in endometrioid and nonendometrioid cancers. Grade 1 and 
2 tumors and carcinomas having myometrial invasion less than 50% have higher survivin expression. These results supports 
that, survivin may play an important role in early stage tumors and early phases of tumor development. We did not find any 
association between matrix metalloproteinase­2 expression and classical prognostic factors in endometrial cancer and both 
proteins were not associated with survival.
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are mutations of PTEN, K­Ras, CTNNB1 (beta­catenin) genes 
and microsatellite instability (MSI), but they rarely exhibit p53 
mutations [1,4,5]. In contrast, nonendometrioid carcinomas 
often exhibit p53 tumor suppressor gene mutations and 
loss of heterozygosity located on several chromosomes, but 
occasionally have MSI [6,7] Unfortunately, none of these mo­
lecular markers are prognostic enough for endometrial cancer, 
and new prognostic markers are necessary.
Matrix metalloproteinases (MMPs) are a family of zinc­depen­
dent endopeptidases which degrade the extracellular matrix 
and play an important role in tumor invasion and progression 
[8]. MMPs are expressed at low levels in normal adult tissues, 
except in tissues that undergo remodeling such as the cyclic 
endometrium and the skin during wound healing [9­11]. Also, 
MMP­2 expression has been shown to be increased in several 
human neoplasias such as breast, ovary and colon cancers, 
and it seems to correlate with their invasion and metastatic 
be  haviours [9]. Recently, MMP­2 has been demonstrated in 
en  do  metrial carcinoma cells but there are only a few studies 
comparing MMP­2 expression between type I and type II en­
do  metrial carcinoma [12,13].
Survivin is a novel and structurally unique member of the 
in  hibitor apoptosis (IAP) family of antiapoptotic proteins. Its 
gene is located on chromosome 17q25 [14]. Unlike other IAP 
proteins, survivin was found during fetal development, is not 
detectable in normal adult tissues, and became reexpressed 
in all of the most common human cancers [15,16]. Recently, 
in several studies, overexpression of survivin has been shown 
to be associated with endometrial carcinoma, but there are 
con  flicting results for the impact on prognosis of endometrial 
carcinoma [17­19]. The nuclear or cytoplasmic expression of 
sur  vivin is controversial. Immunofluorescence studies show  e  d 
that survivin was expressed mainly in the nucleus of en  do  me­
trial carcinoma cells, whereas previous studies reported that it 
is restricted to the cytoplasm [18]. 
This study aimed to investigate the expression of MMP­2 
and survivin in surgically treated endometrial cancer patients. 
MMP­2 and survivin expressions were compared in type I and 
type II tumors, and the correlation of these markers between 
well­established prognostic factors and the relationship with 
survival were analyzed.
MATERIALS AND METHODS
1. Patients and specimens
This study was approved by the institutional review 
board at Dokuz Eylul University Faculty of Medicine. For 
immunohistochemical analysis, ninety­five patients with 
primary endometrial carcinoma, including 74 endometrioid 
and 21 nonendometrioid carcinomas, were selected from 
the pathology archive. All patients were surgically treated, 
histologically diagnosed and given follow­up care at the 
Division of Gynecologic Oncology, Department of Obstetrics 
and Gynecology at Dokuz Eylul University Faculty of Medicine. 
Certain clinical and pathologic parameters were recorded, 
including details on age, histopathologic type, tumor stage, 
tumor grade, and follow­up. The tumors were classified 
according to the histologic typing of the female genital 
tract by the World Health Organization, staged and graded 
according to the International Federation of Gynecology 
and Obstetrics (FIGO) systems [20,21]. Standard hematoxylin 
and eosin (H&E)­stained sections of formalin­fixed, paraffin­
embedded tumor tissues were reviewed to confirm the 
histopathologic diagnosis; 73 cases were classified as FIGO 
stage 1, 6 cases as stage 2 and 16 cases as stage 3. All patients 
were followed up until death or a median of 39 months (range, 
9 to 151 months).
2. Immunohistochemistry
Five mm sections were taken onto poly­L lysin­coated 
slides from each representative archival paraffin­embedded 
tumor tissue for immunohistochemical staining. The 
standard streptavidin biotin immunoperoxidase method 
was performed using the primary antibodies against survivin 
(1/100, Diagnostic Biosystems, Pleasanton, CA, USA) and 
MMP­2 (1/50, Diagnostic Biosystems). Briefly, sections were 
deparaffinized in xylene, rehydrated in alcohol series, and 
immersed in distillated water. Endogenous peroxidase activity 
was blocked using a 0.3% solution of hydrogen peroxide in 
phosphate­buffered saline (0.01 mmol/L, pH 7.5) at room 
temperature for 15 minutes and rinsed with TRIS buffer. 
After antigen retrieval by heating in 10 mmol/L citrate buffer 
(pH 6.0) for 30 minutes, primary antibodies were applied 
for 60 minutes at room temperature and washed in TRIS 
buffer. Biotinylated secondary antibodies and streptavidin­
peroxidase complex were added consecutively for 10 minutes 
at room temperature and washed in TRIS buffer. Peroxidase 
activity was visualized with 0.03% 3­3’ diaminobenzidine 
tetrahydrochloride applied for 7 minutes. After rinsing in 
deionized water and counterstaining in Mayer’s hematoxylin, 
the slides were dehydrated and mounted. Appropriate tissue 
sections as positive controls for each primary antibody were 
also stained simultaneously. As a negative control, sections 
were processed in the absence of primary antibody.
3. Immunohistochemical evaluation
Immunohistochemical staining in tumor cells was evaluated Matrix metalloproteinase-2 and survivin in endometrial cancers
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in a semiquantitative fashion. For the survivin antibody, both 
cytoplasmic and nuclear staining were observed and evalu  a­
te  d. For MMP­2, only cytoplasmic staining was observed and 
evaluated. The degree of staining for survivin and MMP­2 was 
evaluated by scoring on a scale from 0 to 4 for intensity (I) and 
for distribution (D). Tissues with IxD equal to 0 were consi  der  ed 
negative, those with less than or equal to 4 were weakly po  si­
tive, and those with greater than 4 were strongly positive [22]. 
Results were also further simplified as positive and negative.
4. Statistical analysis
Data analyses were performed using SPSS 15.0 (SPSS Inc., 
Chicago, IL, USA). The relationship between immunohisto  che­
mical scores, tumor stage and histologic and nuclear grade 
was investigated by using the chi­squared test. Survival analy­
ses were calculated by using the Kaplan­Meier method. The 
long rank test was used for univariate, and Cox proportional 
hazards regression model for the multivariate evaluation. The 
probability level 0.05 or less was chosen to represent statistical 
significance. 
RESULTS
A total of ninety­five patients with endometrial carcinoma 
were included in the present study. There were 74 (77.9%) 
endometrioid (type I) and 21 (22.1%) non­endometrioid (type 
II) carcinomas. The median age of the patients was 61 years 
(range, 34 to 87 years). Clinicopathologic characteristics of the 
cases are shown in Table 1.
Distribution of MMP­2 and survivin staining in 95 endometri­
al tumors are shown in Table 2. For survivin, positive cytoplas­
mic and nuclear immunohistochemical staining was seen in 
73.7% and 66.3% respectively, and also MMP­2 on 66.3% of all 
tumors (Figs. 1 and 2). Survivin nuclear expression was higher 
in endometrioid endometrial carcinoma (EEC) compared 
to non­EEC (NEEC), and this was statistically significant (p= 
0.040), but there was no statistically significant relationship 
be  t  ween cytoplasmic survivin and MMP­2 expressions be  t­
ween type I and type II carcinomas. Table 3 summarizes the 
clinicopathologic characteristics of 95 patients with endo­
me  t  rial carcinoma and their association with the expression 
of survivin and MMP­2. There was no relationship between 
Table 1. Distribution of clinicopathologic characteristics in 95 patients 
with endometrial carcinoma
Characteristics Values
Total 95 (100)
Histology
    Endometrioid 74 (77.9)
    Non endometrioid 21 (22.1)
Stage
    Stage I  73 (76.8)
    Stage II+III 22 (23.2)
Histological grade
    1 30 (31.6)
    2 36 (37.9)
    3 29 (30.5)
Myometrial invasion
    No   7 (7.4)
    <50% 40 (42.1)
    >50% 48 (50.5)
Vascular/lymphatic invasion   9 (9.47)
    Yes   86 (90.53)
    No 61±10.26 (34-78)
Age (yr) 60 (63.2)
    <65 35 (36.8)
    >65  53±37.98 (9-151)
Follow-up duration (mo) 
Local recurrence 3 (3.15)
    Yes 92 (96.85)
    No
Metastasis 5 (5.26)
    Yes 90 (94.74)
    No  9 (9.47)
Death 
Values are presented as number (%) or mean±SD (range).
Table 2. Distribution of MMP-2 and survivin staining in 95 patients 
in endometrial cancer and comparison with endometrioid and 
nonendo  met  rioid type
Staining Total
Endo-
metrioid 
(type I)
Nonendo-
metrioid 
(type II)
p-value
MMP-2 0.878
  Negative 33 (34.7) 26 (35.1)   7 (33.3)
  Positive 62 (66.3) 48 (64.9) 14 (66.7)
Survivin (nuclear) 0.040
  Negative 32 (33.7) 21 (28.4) 11 (52.4)
  Positive 63 (66.3) 53 (71.6) 10 (47.6)
Survivin (cytoplasmic)  0.408
  Negative 25 (26.3) 18 (24.3)   7 (33.3)
  Positive 70 (73.7) 56 (75.7) 14 (66.7)
Total 95 (100) 74 (100) 21 (100)
Values are presented as number (%).
MMP, matrix metalloproteinases.Evren Yilmaz, et al.
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sur  vivin cytoplasmic, survivin nuclear and MMP­2 expressions 
and lymphovascular space involvement and extrauterine di­
sease. However survivin cytoplasmic staining was significantly 
lower in patients with deep myometrial invasion (p=0.038). 
The percentage of survivin nuclear staining cells in histologic 
grade 1, 2 and 3 tumors were 24.2%, 28.4% and 13.7%, res  pec­
ti  vely. Nuclear expression of survivin was decreased in histo­
lo  gic grade 3 tumors compared to grade 1 and 2 tumors, but 
there was no difference between grade 1 and 2. Adversely, the 
survivin cytoplasmic and MMP­2 expressions were decreased 
in grade 3 tumors but not statistically significant.
Follow­up data were available for all patients. The median 
duration of follow­up was 39 months (range, 9 to 151 months). 
During the follow­up, 3 local recurrences, 2 solid organ 
metastasis, and 3 lymph node metastasis were documented. 
Overall mean cumulative survival of the patients was 134.30
±5.46 months, and the cumulative overall and disease­free 
survival rates were 0.822 and 0.821, respectively. The mean 
survival related to survivin nuclear, cytoplasmic and MMP­2 
expression is shown in Table 4. While the mean cumulative 
survival was 140.96 months in stage I cases, it dropped to 
110.22 months in the advanced stage group (p=0.0054). Also, 
the cumulative survival rates of patients with type I tumors 
were significantly higher than those of patients with type II 
tumors (p<0.001). Cox regression analysis showed that stage, 
grade and histological type have an independent impact on 
survival. We did not find any statistically significant difference 
between survivin or MMP­2 expressions and survival (p>0.05) 
(Table 4).
DISCUSSION
MMP­2 and survivin expressions and their relationships with 
the clinical behaviors and histologic types of endometrial 
cancers were investigated in this study. In our present study, 
MMP­2 expression did not show any difference between 
EEC and NEEC carcinomas. These results confirm those of 
Graesslin et al. [13]. On the other hand, Shaco­Levy et al. [23] 
found increased MMP­2 expression in NEEC as compared 
to EEC. In another study, Monaghan et al. [12] showed that 
significantly greater MMP­2 expression was present in EEC 
compared to NEEC. The difference between these two 
studies could be attributed to the fact that the two study 
groups were not homogenous in terms of tumor stage and 
grade. There have been only a few studies investigating the 
relationship between matrix metalloproteinase expression 
Fig. 1. Survivin cytoplasmic (A) and nuclear (B) immunohistochemical staining in pT3a endometrioid endometrial adenocarcinoma (×400).
Fig. 2. Matrix metalloproteinase-2 positivity in pT1b endometrioid 
endometrial adeno  carcinoma (×100).Matrix metalloproteinase-2 and survivin in endometrial cancers
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Table 3. Clinicopathologic characteristics of 95 cases and association with survivin and MMP-2 expressions
Clinicopathologic 
feature
Comparison of staining patterns
Survivin nuclear
p-value
Survivin cytoplasmic
p-value
MMP-2
p-value
Negative  Positive Negative Positive Negative Positive
Stage 0.628 0.790 0.160
    Stage I 23 (24.2) 50 (52.6) 18 (18.9) 55 (57.9) 22 (23.1) 51 (53.7)
    Stage II+III 9 (9.5) 13 (13.7) 7 (7.3) 15 (15.8) 11 (11.6) 11 (11.6)
MI 0.612 0.012 0.316
    <50% 17 (17.9) 30 (31.6) 7 (7.4) 40 (42.1) 14 (14.7) 33 (34.7)
    >50% 15 (15.8) 33 (34.7) 18 (18.9) 30 (31.6) 19 (20) 29 (30.6)
Histologic grade 0.013 0.229 0.648
    1 7 (7.4) 23 (24.2) 6 (6.3) 24 (25.3) 10 (10.5) 20 (21.1)
    2 9 (9.5) 27 (28.4) 8 (8.4) 28 (29.5) 11 (11.6) 25 (26.3)
    3 16 (16.8) 13 (13.7) 11 (11.6) 18 (18.9) 12 (12.6) 17 (17.9)
LVI 0.354 0.562 0.619
    Yes 4 (4.2) 5 (5.3) 2 (2.1) 7 (7.4) 3 (3.2) 6 (6.3)
    No 28 (29.5) 58 (61.1) 23 (24.2) 63 (66.3) 30 (31.6) 56 (58.9)
Values are presented as number (%).
MMP, matrix metalloproteinases; MI, myometrial invasion; LVI, lymphovascular invasion.
Table 4. Results of survival analysis
Kaplan-Meier COX regression
Events/total p-value* OR (95% CI) p-value
Stage     0.0054   4.2 (1.01-18.2) 0.04
    Early (stage I) 4/73
    Late (stage II and III) 5/22
Histology <0.001 17.6 (3.2-94.98) 0.001
    Endometrioid 2/74
    Non endometrioid 7/21
Histologic grade  0.024   3.5 (1.1-11.13)  0.029
    Grade 1 0/30
    Grade 2 3/36
    Grade 3 6/29
MMP-2  0.945 0.9 (0.2-4.04) 0.909
    Negative 3/33
    Positive 6/62
Survivin (nuclear)  0.816     2.6 (0.59-12.09) 0.199
    Negative 3/32
    Positive 6/63
Survivin (cytoplasmic)  0.197 0.2 (0.07-1.2) 0.096
    Negative 4/25
    Positive 5/70
OR, odds ratios; CI, confidence interval; MMP, matrix metalloproteinases.
*Log-rank test.Evren Yilmaz, et al.
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and survival in endometrial cancer patients. Previous studies 
have shown that, MMP ­1, MMP­2 or MMP­9 and membrane­
type 1 (MT1)­MMP proteins or mRNAs exist in endometrial 
cancer tissues [24,25]. Di Nezza et al. [26] revealed that MMP­
2 and MMP­9 expressions in tumor cells are increased in the 
transition from histologic grade 1 to grades 2 and 3. These 
results are supported by other studies [13,25]. On the other 
hand, Lopata et al. [27], with use of gelatin zymography, 
revealed that elevated levels of latent and active forms of 
MMP­2 are detected in uterine lavage samples from patients 
with endometrial cancer, and they found no significant 
association between the MMP score and the histologic grade 
of tumor. Likewise, Honkavuori et al. [28] did not determine 
any correlation between MMP­2 immunostaining and 
histological grade. These results are consistent with our study. 
Furthermore, we did not find any correlation between the 
MMP­2 score and the FIGO stage, vascular/lymphatic invasion, 
or depth of myometrial invasion. These results agree with 
those of other authors [25,26,28,29]. Graesslin et al. [13] found 
that high MMP­2 expression is correlated with only lymph 
node metastasis, but that there is no association with other 
clinical features of endometrial cancer. Their results are in 
keeping with the study of Iurlaro et al. [30] Survival analyses 
have been rarely performed in previous studies. Moser et al. 
[24], Aglund et al. [25], and, recently, Honkavuori et al. [28] 
found no statistically significant correlation between MMP­2 
expression and overall survival in endometrial cancer. Similarly, 
in the present study, we did not find any association between 
survival and the MMP­2 staining score.
Survivin, a member of the IAP family, has been detected to be 
over expressed in 60 human cancer types studied, including 
en  dometrial carcinoma [31,32]. Although some immu  no  his­
to  chemical studies suggested that survivin expression occurs 
primarily in the nucleus and partially in the cytoplasm of en­
do  metrial cancer cells, Pallares et al. [33] found that most of 
the survivin proteins were cytoplasmic. The present study 
did not determine statistically significant difference be  t­
ween cytoplasmic and nuclear expressions. In a small num­
ber of previous reports investigating the role of survivin 
in the endometrial cancer, controversial results have been 
obtained [17,18,33­35]. Saitoh et al. [34] demonstrated that 
levels of survivin mRNA in endometrial cancer samples were 
significantly higher than the levels that were seen in the nor­
mal endometrium, and did not show any correlation with 
his  tologic grade of the tumors. Similarly, in their study, Ai et 
al. [32] showed that survivin protein expression levels were 
significantly higher in endometrial cancer cells than atypical 
or normal endometrium, and were not different between 
type 1 and type 2 endometrial cancers. Also, they did not 
ob  ser  ve any association with patient age, tumor grade and 
stage, and these results were supported by Pallares et al. [33]. 
In our present study, unlike the results of Ai et al. [32], survivin 
nuclear expression was higher in EEC as compared to NEEC. 
This difference may be due to the nonhomogenous stage 
dis  tribution in type 1 and type 2 patient groups in the above 
studies including ours. Lehner et al. evaluated survivin mRNA 
levels in both normal endometrium and endometrial cancer 
specimens, and suggested that survivin mRNA is not a specific 
marker of endometrial cancer. In contrast to the studies of Ai et 
al. [32] and Pallares et al. [33], Lehner et al. [35] suggested that 
survivin mRNA expression only correlates with the histologic 
grade of the tumors. The study of Takai et al. [18], supporting 
the results of Lehner et al. [35], showed that survivin protein 
expressions within endometrial carcinoma cells were sig  ni­
fi  cantly associated with significant clinicopathologic prog­
no  stic parameters and survival rates. Recently, at another 
im  mu  no  histochemical study of Erkanli et al. [17], they showed 
survivin expression to be increased in a spectrum from normal 
to hyperplastic endometrium and to endometrial cancer. 
Also, different from Takai et al. [18], they have reported no 
correlation between survivin and classical prognostic factors 
or survival rates in endometrial carcinomas. Eventually these 
authors concluded that these findings suggest that survivin 
overexpression is one of the most important factors in the 
developmental pathway of endometrioid carcinomas [17]. 
Likewise, in our study, we found that nuclear expression of 
survivin is decreased in histologic grade 3 tumors compared 
to both grade 1 and grade 2 tumors, and survivin cytoplasmic 
expression was significantly lower in patients with deep myo­
metrial invasion (p=0.038). These results differ from other stu­
dies, supporting the suggestion in the study of Erkanli et al., 
and may be explained as survivin expression playing a role in 
the earlier stages or development of tumor, but not in tumor 
aggressiveness of it. Also, in our study, we did not find any 
rela  tion between survivin expression and clinical prognostic 
factors including lymphovascular space involvement and 
ex  tra  uterine disease or survival. However, these results are 
not consistent with the study of Lambropoulou et al. [19]. 
They found a significant correlation survivin expression with 
myometrial invasion, histological grade, stage and survival 
rates. This difference may be due to different staining criteria. 
In conclusion, differing from those of previous studies, we 
have shown that in histologic grade 1 and 2 tumors and cases 
with myometrial invasion less than 50%, survivin expression 
was found to be higher. These results support the hypothesis 
that survivin may play an important role in early stage tumors 
and early phases of tumor development. However, we did not 
find any association between MMP­2 expression and classical Matrix metalloproteinase-2 and survivin in endometrial cancers
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prognostic factors in endometrial carcinoma, additionally 
both proteins were not associated with survival. As far as 
we know our study includes the largest number of cases of 
both survivin and MMP­2 expression in the literature. Further 
studies with longer follow­up and larger number of cases are 
needed. 
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